Germany: Inescapable trap for German parts of European patents not inescapable

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: Inescapable trap for German parts of European patents not inescapable

Contrary to the very strict approach at the EPO in the situation in opposition proceedings referred to as the inescapable trap (where the patentee is squeezed between Article 123(2) and Article 123(3) EPC), which almost exclusively leads to the revocation of a European patent, Germany's Federal Supreme Court (BGH) has established a more liberal practice of dealing with such a situation for national German patents (see in particular the BGH's decision Xa ZB 14/09 Winkelmesseinrichtung).

In Managing IP's edition of October 2014, we reported on decision 4 Ni 34/12 (EP) Fettsaugeabrichtung by Germany's Federal Patent Court (BPatG). In this decision, the BPatG clarified that the above-mentioned case law established for national German patents does not apply to German parts of European patents. The decision could be interpreted such that this opens up a further opportunity for a third party who missed the nine-month opposition deadline in Europe to attack the German part of a European patent in nullity proceedings.

The above no longer applies in view a recent decision by the BGH, Germany's highest instance in patent matters. Although this decision by the BGH (X ZR 161/12 Wundbehandlungsvorrichtung) is not related to the above-mentioned BPatG-decision, the BGH explicitly referred to Fettsaugeabrichtung and took the opposite view of the BPatG. Thus, also the German parts of European patents may be maintained in German nullity proceedings according to the practice established for national German patents.

The BGH based its decision inter alia on Article II § 6 IntPatÜbkG. According to this Article, the nullity grounds for the German part of a European patent are listed in Article 138 EPC. While the BGH acknowledged that Article 138 EPC lists the grounds in an exclusive manner, the BGH went on to say that it is nevertheless possible for a national court to desist from declaring a patent null even if such a ground is present. The BGH further referred to Article 14 GG and stated that the constitutional protection of property including the right on a patent must be protected against unnecessary sovereign intervention. It seems that the BGH balanced this against the very strict inescapable trap approach in EPO practice.

Ledl_Andreas

Andreas Ledl


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

By accepting a relatively small sample of infringing content to grant worldwide relief, a UK court has adopted a pragmatic approach that could reduce the time and expense involved in huge enforcement actions
This year’s IP STARS Americas rankings reveal that firms are expanding their capabilities, particularly in trade secrets and life sciences
Law firms’ expanding IP capabilities are driving broader industry recognition across a wider range of practice areas
As specialist boutiques challenge traditional firm models, major disputes involving Disney, Ericsson, Siemens and Dolby highlight the firms winning work before the UPC
The firm has added two leading damages specialists as it expands beyond technical analysis and deepens its role in the economics of IP litigation
Josh Seidenfeld, partner at DLA Piper, outlines the emerging legal trends that drive the future of life sciences innovation and how stakeholders can prepare for the future
South Korea's One Law Partners is combining with boutique firm Minwho Law Group to leverage global expansion of K-content and build a broader offering spanning IP, tech and regulatory advisory work
Russell Kennedy's Gina Tresidder on juggling matters, delivering hard truths, and why IP ownership is rarely as simple as people think
Attorney Oran Friar and trainee attorney Harry Cunliffe at Reddie & Grose, share that patent filings for clinical LLMs are surging, but success in the UK and Europe hinges on demonstrating technical innovation
Implementers can use the UK courts to seek FRAND terms for patent pool licences
Gift this article